Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety, tolerability and immunogenicity of Biological E's CORBEVAX™ vaccine in children and adolescents: A prospective, randomised, double-blind, placebo controlled, phase-2/3 study.
Thuluva S, Paradkar V, Gunneri S, Yerroju V, Mogulla RR, Suneetha PV, Turaga K, Kyasani M, Manoharan SK, Adabala S, Sri Javvadi A, Medigeshi G, Singh J, Shaman H, Binayke A, Zaheer A, Awasthi A, Narang M, Nanjappa P, Mahantshetti N, Swarup Garg B, Pandey AK. Thuluva S, et al. Among authors: yerroju v. Vaccine. 2022 Nov 22;40(49):7130-7140. doi: 10.1016/j.vaccine.2022.10.045. Epub 2022 Oct 31. Vaccine. 2022. PMID: 36328879 Clinical Trial.
Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trials.
Thuluva S, Paradkar V, Gunneri SR, Yerroju V, Mogulla R, Turaga K, Kyasani M, Manoharan SK, Medigeshi G, Singh J, Shaman H, Singh C, Rao A V. Thuluva S, et al. Among authors: yerroju v. EBioMedicine. 2022 Sep;83:104217. doi: 10.1016/j.ebiom.2022.104217. Epub 2022 Aug 12. EBioMedicine. 2022. PMID: 35970020 Free PMC article. Clinical Trial.
Immunogenicity and safety of a 14-valent pneumococcal polysaccharide conjugate vaccine (PNEUBEVAX 14™) administered to 6-8 weeks old healthy Indian Infants: A single blind, randomized, active-controlled, Phase-III study.
Matur RV, Thuluva S, Gunneri S, Yerroju V, Reddy Mogulla R, Thammireddy K, Paliwal P, Mahantshetty NS, Ravi MD, Prashanth S, Verma S, Narayan JP. Matur RV, et al. Among authors: yerroju v. Vaccine. 2024 May 10;42(13):3157-3165. doi: 10.1016/j.vaccine.2024.03.056. Epub 2024 Apr 17. Vaccine. 2024. PMID: 38637211 Clinical Trial.
A phase II/III randomised, comparative study evaluating the safety and immunogenicity of Biological E's live, attenuated Measles-Rubella vaccine in 9-12 month old healthy infants.
Thuluva S, Gunneri S, Turaga K, Mogulla RR, Yerroju V, Peta K, Suneetha PV, Matur RV. Thuluva S, et al. Among authors: yerroju v. Contemp Clin Trials Commun. 2023 Nov 22;36:101232. doi: 10.1016/j.conctc.2023.101232. eCollection 2023 Dec. Contemp Clin Trials Commun. 2023. PMID: 38058513 Free PMC article.
Immunogenicity and safety of Biological E's CORBEVAX™ vaccine compared to COVISHIELD™ (ChAdOx1 nCoV-19) vaccine studied in a phase-3, single blind, multicentre, randomized clinical trial.
Thuluva S, Paradkar V, Gunneri S, Yerroju V, Mogulla R, Suneetha PV, Turaga K, Kyasani M, Manoharan SK, Adabala S, Sri Javvadi A, Medigeshi G, Singh J, Shaman H, Binayke A, Zaheer A, Awasthi A, Singh C, Rao A V, Basu I, Kumar KAA, Pandey AK. Thuluva S, et al. Among authors: yerroju v. Hum Vaccin Immunother. 2023 Dec 31;19(1):2203632. doi: 10.1080/21645515.2023.2203632. Epub 2023 Apr 27. Hum Vaccin Immunother. 2023. PMID: 37113012 Free PMC article. Clinical Trial.